SCHEMBL1089205

SCHEMBL1089205

COc1ccc(CC(=O)N2CCCC(N3CCCC(Nc4nccc(N5CCCCCC5)n4)C3)C2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.48
GAA P10253 1/20 0.48
ALK Q9UM73 2/20 0.47
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CXCR4 P61073 1/20 0.45
MAPK10 P53779 2/20 0.44
CCNK O75909 1/20 0.44
CDK12 Q9NYV4 1/20 0.44
SLC2A1 P11166 1/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
IGF1R P08069 1/20 0.42
LCK P06239 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
GFER P55789 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1091225 0.99 HPGD (0.47) HPGDGAAALKNPSR1HSD17B10
SCHEMBL1090345 0.97 HPGD (0.48) HPGDGAAALKNPSR1HSD17B10
SCHEMBL1091032 0.93 HPGD (0.48) HPGDGAAALKNPSR1HSD17B10
SCHEMBL1090930 0.91 HPGD (0.48) HPGDGAAALKNPSR1HSD17B10
SCHEMBL1091303 0.91 POLB (0.52) ALKL3MBTL1CXCR4MAPK10CCNK
SCHEMBL1090721 0.90 POLB (0.51) ALKCXCR4MAPK10CCNKCDK12
SCHEMBL1090377 0.90 MRGPRX1 (0.49) ALKCXCR4MAPK10CCNKCDK12
SCHEMBL1090902 0.90 CXCR4 (0.57) ALKCXCR4MAPK10CCNKCDK12
SCHEMBL1090311 0.89 HPGD (0.49) HPGDGAAALKNPSR1HSD17B10
SCHEMBL1091240 0.89 MRGPRX1 (0.48) ALKCXCR4MAPK10CCNKCDK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 HPGD 34/4885GAA 4229/4885ALK 882/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 HPGD 34/4885GAA 4229/4885ALK 882/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 HPGD 34/4885GAA 4229/4885ALK 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.